Page last updated: 2024-10-29

indirubin-3'-monoxime and Osteosarcoma

indirubin-3'-monoxime has been researched along with Osteosarcoma in 2 studies

indirubin-3'-monoxime: has antiangiogenic activity
indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.

Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Fu, B1
Yin, G1
Song, K1
Mu, X1
Xu, B1
Zhang, X1
Zhang, Y2
Song, L1
Li, J1
Lu, X1
Zhang, B1

Other Studies

2 other studies available for indirubin-3'-monoxime and Osteosarcoma

ArticleYear
Indirubin-3'-Oxime (IDR3O) Inhibits Proliferation of Osteosarcoma Cells in vitro and Tumor Growth in vivo Through AMPK-Activation and PGC-1α/TFAM Up-Regulation.
    Doklady. Biochemistry and biophysics, 2020, Volume: 495, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferat

2020
Inhibitory effects of indirubin-3'-monoxime against human osteosarcoma.
    IUBMB life, 2019, Volume: 71, Issue:10

    Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Focal Adhesion

2019